Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy
Blood and Lymphatic Cancer: Targets and Therapy
- View all (140)
- Volume 16, 2026 (14)
- Volume 15, 2025 (19)
- Volume 14, 2024 (6)
- Volume 13, 2023 (7)
- Volume 12, 2022 (12)
- Volume 11, 2021 (6)
- Volume 10, 2020 (2)
- Volume 9, 2019 (7)
- Volume 8, 2018 (7)
- Volume 7, 2017 (8)
- Volume 6, 2016 (5)
- Volume 5, 2015 (11)
- Volume 4, 2014 (13)
- Volume 3, 2013 (6)
- Volume 2, 2012 (12)
- Volume 1, 2011 (5)
Journal Articles:
- 140 records -
Short-Term Longitudinal Analysis of Gut Microbiota Dynamics During Anti-CD19 CAR-T Cell Therapy in Diffuse Large B-Cell Lymphoma Patients
Shen Z, Xing X, Rong K, Geng Z, Yang N, Xu L, Ge H, Sang W
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:598958
Published Date: 1 May 2026
Poor Outcome of Pediatric Patients with Acute Lymphoblastic Leukemia Harboring Low P16 Deletion Ratio: A Post-Hoc Analysis from a Prospective Cohort
Qiu KY, Liao XY, Chen HL, Zheng H, Fang JP, Zhou DH
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:592290
Published Date: 30 April 2026
Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review
Aljumaa M, Hamam Refai H, Chawla Y, Gonsalves WI
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:586948
Published Date: 27 April 2026
Enzymatic Laccase Nanoreactors Induce Apoptosis in MOLT-4-ALL Cells and Activate Prodrugs in a Synergetic Effect
Medrano-Villagómez CA, Loredo-García E, Gasperin-Bulbarela J, Vazquez-Duhalt R
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:576292
Published Date: 27 April 2026
Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study
Zhao N, Zhu L, Hu X, Tong J, Ge H, Ye L, Zhu X, Gai C, Feng Y, Zhang L, Wang L, Sun G, Xue L, Zhu X, Zheng C
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:592550
Published Date: 24 April 2026
Prognostic Value of the Aggregate Inflammation Systemic Index (AISI) in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Study
Chen X, Huang L, Zhang Q, Xing X, Zhang S, Wang C, Wang L, Shen Z, Sang W
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:571663
Published Date: 31 March 2026
Crosstalk Between FOXN3 and E2F5 Reveals a Novel Tumor Suppressive Pathway in Acute Myeloid Leukemia via MAPK Signaling: Implications for Potential Future Targeted Therapy
Zhang J, Jiang Q, Liu T, Li H, Liang Y, Lu X, Pang H, Li S, Li Y, Zhang R
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:571966
Published Date: 24 March 2026
Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2
Espinoza-Gutarra MR, Jarrett BA, Wang X, Afghahi A, Bae S
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:559759
Published Date: 12 March 2026
Construction and Validation of an N7-Methylguanosine–Related Prognostic Model for Acute Myeloid Leukemia
Wang L, Li M, Xi Y
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:575337
Published Date: 11 March 2026
Association Between Petroleum Compounds Exposure and Risk of Childhood Leukemia: A Systematic Review
Soliman HMH, Hassan WY, Mostafa M, Gomaa MK, Soliman Jnr MH, Hussein MF
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:571340
Published Date: 11 February 2026
Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic lymphohistiocytosis—a Rare and Dangerous Disease
Meng G, Wang M, Sun C, Feng G, Ren J, Feng S, Wang Y
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:574445
Published Date: 27 January 2026
Safety and Efficacy of Flumatinib in Patients with Chronic Phase Chronic Myeloid Leukemia: A Real-Life Cohort Observational Study
Cheng F, Cui Z, Li Q, Wang L, Li W
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:573070
Published Date: 22 January 2026
Study on the Role of Neutrophil Extracellular Traps-Based Risk Model and Discriminative Gene LTF in the Prognosis of Acute Myeloid Leukemia and the Regulation of Immune Microenvironment
Li Y, Zhang J, Liu T, Zhang D, Wang N, Liu X, Feng P, Zhang J, Ji C, Ye J
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:562651
Published Date: 13 January 2026
Global Patterns, Temporal Trends, and Potential Non-Infectious Risk Factors for Burkitt Lymphoma from 1990 to 2021
Jin SK, Lyu JT, Feng ZY, Zhang SQ, Lu BY, Yan QF, Li J, Du J, Huang ZF
Blood and Lymphatic Cancer: Targets and Therapy 2026, 16:556459
Published Date: 8 January 2026
Expression and Clinical Significance of BCL2 Interacting Protein 3 Like (BNIP3L) in Serum of Patients with MM
Nong Y, Xiong Z, Wang Q, Gu M, Zheng Y, Wang Y, Wu J, Huang C, Li Z, Luo J, Ling Z, Li R
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:247-264
Published Date: 17 December 2025
LRG1 Drives AML Progression by Disrupting Myeloid Progenitor Regulation
Guo R, Wu P, Yao S, Liu F
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:235-246
Published Date: 17 December 2025
Alantolactone Inhibits Double Expression Lymphoma via Dual-Targeted Glycogen Synthase Kinase 3 Beta and B-Cell Lymphoma2
Chen J, Liao Q, Yang S, Bian J, Li X, Zhao L, Wen D, Bai D, Yu C, Zhou C, Xu Z
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:217-233
Published Date: 12 December 2025
Phase II Trial of an Orelabrutinib-Based Combination Therapy in Newly Diagnosed Primary Central Nervous System Lymphoma
Zhao Y, Liu X, He Q, Yu Y, Xu L, Sun C, Liu G, Wang L, Ma J
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:203-216
Published Date: 6 December 2025
Venetoclax Plus Blinatumoma as First Line Therapy for Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia
Lei Y, Zhao X, Huang H, Duan L, Xu J, Miao K, Zhao H, Qiao C, Hong M, Qian S, Fan L, Zhu Y
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:193-202
Published Date: 5 November 2025
The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies
Reynolds SB, Komrokji R, Kuykendall AT
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:181-192
Published Date: 24 September 2025
Comprehensive Analysis of Tumor Microenvironment and PD-L1 Expression Associations with Clinicopathological Features and Prognosis in Diffuse Large B-Cell Lymphoma
Xie YL, Ke LF, Zhang WW, Kang F, Lu SY, Wu CY, Zhu HH, Wang JC, Chen G, Chen YP
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:167-179
Published Date: 6 September 2025
Comprehensive Evaluation of Drug-Related Problems and Pharmacotherapy Patterns in Non-Hodgkin’s Lymphoma Patients in Yemen
Battah MM, Zainal H, Ibrahim DA, Md Hanafiah NH, Syed Sulaiman SA
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:149-166
Published Date: 4 September 2025
Serum ATIC Expression as a Novel Diagnostic and Prognostic Biomarker in Multiple Myeloma Patients
Gu M, Zheng Y, Wang Y, Wang Q, Wu J, Xiong Z, Nong Y, Huang C, Li Z, Luo J, Ling Z, Li R
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:133-147
Published Date: 30 August 2025
Neutrophil-Related Genes Predict Prognosis and Contribute to Immunosuppression in Acute Myeloid Leukemia
Zhang D, Li Y, Liu T, Liu X, Zhang J
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:115-132
Published Date: 18 August 2025
Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes
Geng L, Chen E, Ji Y, Liu H, Sun Z
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:103-113
Published Date: 1 August 2025
Clinical Characteristics, Prognostic Risk Factors, and Primary Treatment for Elderly Patients with Primary Central Nervous System Lymphoma: A Seer Database-Based Research
Zhang M, Yang R, Du Y, Feng H, Liu Y, Liu H, Wu D, Niu F, He P
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:85-101
Published Date: 7 July 2025
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]
Zeidan AM, DiNardo C
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:77-83
Published Date: 2 July 2025
Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]
Zeidan AM, Wang E
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:69-75
Published Date: 2 July 2025
Advancing Leukemia Diagnosis and Treatment: WHO-Supported Laboratory Innovations in Africa- A Narrative Review
Obeagu EI
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:47-67
Published Date: 24 June 2025
Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]
Zeidan AM, Loghavi S
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:39-45
Published Date: 21 June 2025
A Monocyte-Driven Prognostic Model for Multiple Myeloma: Multi-Omics and Machine Learning Insights
Xie L, Gao M, Tan S, Zhou Y, Liu J, Wang L, Li X
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:21-37
Published Date: 16 June 2025
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma
Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SM, Vekeman F, Hlavacek P, Meche A, Kim CH, Cislo P, Hughes DM, Nador G, DiBonaventura M
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:11-20
Published Date: 5 June 2025
T-Cell Engagers In Multiple Myeloma: A Clinical Review
Al-Jarrad A, Alouch SS, Chawla Y, Gonsalves WI
Blood and Lymphatic Cancer: Targets and Therapy 2025, 15:1-10
Published Date: 24 March 2025
The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
Almodovar Diaz AA, Alouch SS, Chawla Y, Gonsalves WI
Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:71-87
Published Date: 6 December 2024
Highly Curative Treatment of High-Risk Acute Promyelocytic Leukemia: Induction and Consolidation with ATRA+ATO+anthracyclines and Maintenance with ATRA+RIF
Liu D, Tong J, Chen E, Wang L, Xue L, Zhang X, Zhao N, Hu X, Zheng C
Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:63-69
Published Date: 29 July 2024
Albumin-to-Globulin Ratio Combined with Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor in Multiple Myeloma with Renal Impairment
Zhang Y, Yao X, Zhang Y, Chen Z, Qin Z, Cai Y, Xia W, Hu H
Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:49-62
Published Date: 2 July 2024
Identification of a Prognostic Model Based on NK Cell-Related Genes in Multiple Myeloma Using Single-Cell and Transcriptomic Data Analysis
Mei N, Gong S, Wang L, Wang L, Wang J, Li J, Bao Y, Zhang H, Wang H
Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:31-48
Published Date: 4 June 2024
AC024896.1/miR-363-3p Axis Regulates the Malignant Progression of Acute Myeloid Leukemia by Cuproptosis-Related Gene MYO1B
Zhang J, Zheng Y, Liu H, Liu B
Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:17-30
Published Date: 24 March 2024
Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies
Malfona F, Testi AM, Chiaretti S, Moleti ML
Blood and Lymphatic Cancer: Targets and Therapy 2024, 14:1-15
Published Date: 13 March 2024
Polycythemia Vera: Barriers to and Strategies for Optimal Management
Duminuco A, Harrington P, Harrison C, Curto-Garcia N
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:77-90
Published Date: 21 December 2023
Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review
Alsuhebany N, Pan C, Holovac E, Do B, McBride A
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:67-76
Published Date: 24 November 2023
90Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases
Wang J, Baidoun F, Tun HW, Alhaj Moustafa M
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:59-65
Published Date: 3 October 2023
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article
Hussain M, Yellapragada S, Al Hadidi S
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:33-57
Published Date: 15 September 2023
Successful Anatomy Adapted Therapeutic Management and Genetic Profiling of Primary Pituitary Diffuse Large B-Cell Lymphoma
Kimbrough EO, Gupta V, Jiang L, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:25-32
Published Date: 28 July 2023
Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma
Gessese T, Asrie F, Mulatie Z
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:13-24
Published Date: 29 May 2023
PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
Bou Zeid N, Yazbeck V
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:1-12
Published Date: 8 March 2023
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
Blackmon A, Aldoss I, Ball BJ
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:137-147
Published Date: 6 September 2022
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo MJ, Joseph JJ, Phan LM, DeStefano CB
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:119-136
Published Date: 29 August 2022
Differential Diagnosis of Waldenström’s Macroglobulinemia and Early Management: Perspectives from Clinical Practice
Cingam S, Sidana S
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:107-117
Published Date: 18 August 2022
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
Chung C
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:99-106
Published Date: 4 August 2022